Patients Face High Costs for Essential Drugs: Is Australia's Subsidy System Failing Them?
The Shocking Reality: Many Australians are paying a hefty price for common prescription drugs, and it's not just a few isolated cases. The issue lies within the country's Pharmaceutical Benefits Scheme (PBS), which aims to make essential medicines affordable. But here's where it gets controversial—some drugs are slipping through the cracks, leaving patients with no choice but to pay full price.
The Australian Broadcasting Corporation (ABC) has uncovered a list of everyday medicines, from ear drops to painkillers, that are not covered by the PBS. This means patients are missing out on the scheme's $25 maximum price tag introduced last month. The PBS, designed to cover life-saving and preventive medicines, funds over 900 medicines across 5,000 brands. However, health advocates argue that some regularly used drugs are not being subsidized due to regulatory gaps.
The Unsubsidized List: This list includes incontinence medicines, ear drops, eczema creams, inhalers, Hormone Replacement Therapy (HRT), and painkillers. While these drugs often have moderate prices, ranging from $20 to $100, the long-term use required by patients can lead to substantial financial burdens. Interestingly, it's not that these medicines fail to meet scientific or cost-benefit standards; it's that manufacturers choose not to apply for PBS subsidies for business reasons.
The Impact on Patients: This situation hits pensioners and disadvantaged groups hard. They are unable to access the $7.70 concession price, and the PBS Safety Net scheme offers no relief for long-term use. Elizabeth Deveny, CEO of the Consumers Health Forum of Australia, highlights the struggle for chronically ill patients, who may need multiple medicines each time they visit the pharmacy.
But why don't manufacturers apply for PBS subsidies? In some cases, it's because the Australian market is small, and the cost of applying for PBS listing and negotiating with the government is high. Companies may decide it's more profitable to charge higher prices without PBS restrictions. And this is the part most people miss—it's a commercial decision that affects patients' access to affordable medicine.
Advocates Speak Out: Advocates argue that Australia's subsidy program has a flaw, relying on global market dynamics for funding decisions. They emphasize that for some, access to medicine is more critical than seeing a GP. However, Medicines Australia, representing pharmaceutical companies, offers a different perspective. They suggest that sometimes the patient cohort is too small, or medicines are already cheaper than the $25 co-payment, making PBS listing unnecessary.
Patients Go Without Essential Treatments
A Troubling Example: Urinary incontinence patients, estimated to be up to one-third of Australians over 15, face limited options. Only one drug, oxybutynin, is funded under the PBS, despite six drugs being available. Dr. Ashani Couchman, vice president of the Urological Society of Australia, warns that oxybutynin carries a risk of dementia, making it unsuitable for many aging women who need it most.
Adelaide nurse Amanda Braund, who takes oxybutynin, worries about this risk due to her family history of dementia. She feels forced to choose the cheaper option, hoping for the best. Dr. Couchman explains that patients often pay around $80 monthly for alternatives, totaling nearly $1,000 annually. Many cannot afford this, leading to increased risks of falls, skin ulcers, and social challenges associated with incontinence.
Manufacturer's Perspective: Sanofi, the maker of oxybutynin, advises caution when using their product, Ditropan, in the elderly, as stated in the production information.
Heart Drugs: PBS Restrictions in Focus
Cardiologists also face challenges with drugs listed on the PBS but burdened with numerous restrictions. These include Repatha for cholesterol, Vazkepa for triglycerides, Eliquis as a blood thinner, and bisoprolol, a beta-blocker. The PBS aims to provide timely and affordable access to necessary medicines, but these restrictions often lead to private prescriptions.
The Pharmaceutical Benefits Advisory Committee (PBAC) decides on subsidies, considering health benefits and value for money. Dr. Couchman suggests that specialists and patient groups should have more influence on funding decisions. The Department of Health and Aged Care claims to consider patient and clinician requests for improved access, but practical challenges remain.
Drugs Falling Through the Cracks
The ABC found that drug ownership changes and assumptions about PBAC's favorability can lead to PBS listing delays. Medicines Australia calls for faster reforms to the PBS funding process, as outlined in the Health Technology Assessment (HTA) review. Statistically, only one in four new global market drugs get subsidized in Australia, with up to 1,000 drugs approved by the Therapeutic Goods Administration but rejected by PBAC over a decade.
Medicines Australia's Liz de Somer blames outdated assessment methods, where new drugs are compared to obsolete or unrelated older medicines. The industry seeks faster approval times, currently averaging 466 days, as Australia becomes less attractive for new medicines. However, Elizabeth Deveny points out that even with reforms, companies may not submit drugs for consideration, leaving patients with limited options.
Why Are Some Drugs Not Funded?
Echo Therapeutics, owner of the painkiller Temgesic, chose not to apply for PBS listing due to its addictive nature and short-term use, promoting responsible opioid use. GSK, maker of Avamys nasal spray, cites the removal of intranasal corticosteroids from the PBS before 2008 as a reason for not applying.
An insider reveals that HRT products were unlikely to be listed on the PBS until the federal government's recent announcement to include Estrogel. Novo Nordisk, maker of several HRTs, declined to apply for listing due to commercial reasons. Bayer, producing contraceptives and endometriosis treatments, welcomes PBS listing of more women's health medicines and is reconsidering submissions.
Government's Response and Future Prospects
Dr. Couchman believes regulatory reform can address many issues with a small investment. Health Minister Mark Butler highlights recent additions and changes to the PBS, including new treatments for contraception, menopause, and endometriosis. The government is working on HTA review recommendations and improving patient engagement. They are also exploring faster medicine assessments and researching unmet clinical needs.
The Ongoing Debate: While the government takes steps to improve the PBS, the question remains—are these measures enough to ensure all Australians can access affordable, essential medicines? What do you think? Is the PBS subsidy system failing patients, or are there other factors at play? Share your thoughts and experiences in the comments below, and let's continue this important conversation.
